{"id":1018988,"date":"2026-11-09T16:49:18","date_gmt":"2026-11-09T21:49:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/"},"modified":"2026-11-09T16:49:18","modified_gmt":"2026-11-09T21:49:18","slug":"black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/","title":{"rendered":"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC"},"content":{"rendered":"
\n

Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET<\/p>\n

CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc.<\/a> (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET.<\/p>\n

\n Webcast information<\/strong>\n <\/p>\n

The webcast can be accessed under \u201cEvents and Presentations\u201d on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event for a limited time.<\/p>\n

\n About Silevertinib<\/strong>\n <\/p>\n

Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM, including EGFRvIII, while avoiding the paradoxical EGFR activation reported with reversible TKIs. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.<\/p>\n

In addition to the ongoing Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, the Company is also conducting a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566).<\/p>\n

\n About Black Diamond Therapeutics<\/strong>\n <\/p>\n

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company\u2019s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

For Investors:
investors@bdtx.com<\/a><\/p>\n

For Media:
media@bdtx.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET. Webcast information The webcast can be accessed under \u201cEvents and Presentations\u201d … <\/p>\n

Continue reading “Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018988","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET. Webcast information The webcast can be accessed under \u201cEvents and Presentations\u201d … Continue reading "Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T21:49:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC\",\"datePublished\":\"2026-11-09T21:49:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/\"},\"wordCount\":363,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/\",\"name\":\"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=\",\"datePublished\":\"2026-11-09T21:49:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/","og_locale":"en_US","og_type":"article","og_title":"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC - Market Newsdesk","og_description":"Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET. Webcast information The webcast can be accessed under \u201cEvents and Presentations\u201d … Continue reading \"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T21:49:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC","datePublished":"2026-11-09T21:49:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/"},"wordCount":363,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/","name":"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=","datePublished":"2026-11-09T21:49:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzU4NyM3OTU1MDkxIzIxOTAwNTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-host-webcast-highlighting-updated-silevertinib-phase-2-data-and-fda-feedback-supporting-a-clear-phase-3-path-to-potential-accelerated-approval-in-1l-egfr-ncm-nsclc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018988"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018988\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}